West Pharmaceutical Services WST Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Lifecore Biomedical, Inc.LFCR

——

Charles River LaboratoriesCRL

——

Other financials

Income statement

See full

Revenue$872.3M+13.8%

Gross profit$329.2M+20.2%

Operating income$179.1M+16.5%

Net income$154.0M+16.8%

EPS (diluted)$2.15+18.1%

Balance sheet

See full

Cash & equivalents$435.8M-14.5%

Total debt$316.5M+2.7%

Total equity$3.0B+2.1%

Total assets$4.1B+3.1%

Cash flow

See full

Operating cash flow$124.0M-30.0%

CapEx$43.2M-42.6%

Free cash flow$80.8M-20.7%

Valuation

See full

Market cap$23.72B+30.4%

Enterprise value$23.6B+31.2%

P/E42×+4.7×

P/S7.1×+1.0×

Profitability

See full

Gross margin36.8%+1.5pp

Operating margin20.5%+0.8pp

Net margin17%+0.5pp

FCF margin13.1%+1.5pp

Returns & leverage

See full

Return on equity19.1%+1.4pp

Debt / equity0.1×0.0×

Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: West Pharmaceutical Services’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is West Pharmaceutical Services's other noncash income (expense)?: West Pharmaceutical Services (WST) reported other noncash income (expense) of $6M in Q2 2026.
How has West Pharmaceutical Services's other noncash income (expense) changed year-over-year?: West Pharmaceutical Services's other noncash income (expense) increased by 50.0% year-over-year, from $4M to $6M.